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Introduction {#sec1}
============

The sebaceous gland (SG) is part of the epidermis and produces the sebum that lubricates the skin surface. SGs are often associated with hair follicles (HFs), and loss of sebocyte function can lead to scarring alopecia, indicating a dependence of HFs on SGs ([@bib61]). SG products also form the protective lipid barrier of the skin and thus function in skin immunity ([@bib55]), whereas specialized eyelid SGs (meibomian glands) provide a lipid film to prevent drying of the eye surface ([@bib37]). Sebaceous carcinomas, although rare, often recur locally, frequently metastasize, and have high mortality ([@bib8]). There is therefore considerable interest in elucidating SG biology.

*Myc* was first identified as the cellular homolog of the avian myelocytomatosis viral oncogene (*v-Myc*) ([@bib58]) and originally designated *c-Myc* for cellular-Myc ([@bib21]). MYC is a transcription factor that regulates sebocyte differentiation ([@bib3]; [@bib22]; [@bib62]). *K14MycER* transgenic mice provide an experimental model with which to study MYC-regulated sebocyte differentiation. In these mice, human MYC is expressed under the control of the human keratin 14 (*K14*) promoter as a fusion protein with a mutant mouse estrogen receptor (ER) α ligand-binding domain. The *MycER* transgene is constitutively expressed in the basal layer of the epidermis, but MYCER protein (henceforth MYC) is only activated upon topical activation of 4-hydroxytamoxifen (4OHT). Low levels of MYC activation promote SG expansion and differentiation, whereas high levels stimulate SG proliferation and inhibit differentiation ([@bib7]). MYC is often associated with histone modifications marking active genes ([@bib42]; [@bib46]) and may therefore serve to amplify the program of gene expression dictated by other transcription factors. These observations led us to explore potential factors that influence the outcome of MYC activation in the SG.

The *Ar* has been identified by chromatin immunoprecipitation (ChIP) as a MYC target gene in mouse epidermis ([@bib42]), and MYC can promote androgen receptor (AR) activity and *AR* mRNA expression in human prostate ([@bib40]). In rats and humans, the AR is an early marker of sebocyte differentiation ([@bib5]; [@bib50]). In primary rat preputial sebocyte cultures, androgen inhibits proliferation ([@bib14]). In cultured human sebocytes, androgen can either promote or inhibit proliferation, depending on the type of androgen and the origin of the cells ([@bib1]). In vivo androgens can promote growth and development of the human sebaceous gland ([@bib63]), while poorly differentiated sebaceous carcinomas have reduced AR expression ([@bib5]). Nevertheless, testicular feminization (TFM) mice, which have a spontaneous loss of function *Ar* mutation ([@bib16]), still form SGs ([@bib36]), suggesting the AR is dispensable for morphogenesis.

Another candidate modulator of MYC activity is p53. p53 is mutated in two-thirds of sebaceous carcinomas ([@bib29]). Oncogenic levels of MYC activity promote p53 activation indirectly because of DNA damage ([@bib23]; [@bib39]; [@bib45]). In human sebaceous carcinomas that retain p53 expression, elevated p53 protein levels correlate with worse prognostic outcome ([@bib19]; [@bib20]; [@bib26]).

In the prostate, a mutually antagonistic relationship exists between the AR and p53. p53 can inhibit *AR* gene expression by direct association with the AR promoter ([@bib2]) and by inhibiting AR protein activity ([@bib59]). Conversely, strong AR activity can inhibit *p53* expression ([@bib48]) and p53 activity ([@bib41]). Several of the p53 mutants identified in sebaceous carcinoma ([@bib29]) are also found in prostate cancer and retain the ability to impair AR signaling, despite being mutations in the DNA-binding domain ([@bib43]).

Collectively, these observations prompted us to explore the role of AR and p53 in modulating the consequences of MYC activation in the sebaceous gland.

Results {#sec2}
=======

Markers of SG Differentiation {#sec2.1}
-----------------------------

The SG is a sac-like structure, comprising an undifferentiated, proliferating, peripheral (basal) layer that gives rise to centrally located differentiating sebocytes. As they accumulate lipids, differentiating sebocytes increase in size ([@bib38]; [@bib49]), eventually bursting to release their contents into the sebaceous duct (SD), a thin, cornifying squamous epithelium that connects the SG to the infundibulum of the HF ([@bib32]; [@bib55]). Experimental evidence from DNA label retaining cells ([@bib47]) and lineage tracing has established the existence of SG stem cells (SCs) in the upper HF ([@bib27]; [@bib60]). Their progeny travel around the basal layer to the lower sebaceous tip before transiting internally and upward toward the SD as they undergo terminal differentiation ([@bib13]; [@bib44]) ([Figure 1](#fig1){ref-type="fig"}N).

In telogen back skin of wild-type (WT) mice ([Figures 1](#fig1){ref-type="fig"}A--1M), strong nuclear AR was observed in the lower SG, with weak cytoplasmic and nuclear AR in the upper SG and elsewhere in the epidermis ([Figures 1](#fig1){ref-type="fig"}A and 1B). Proliferative SG cells, marked by Ki67 and proliferating cell nuclear antigen (PCNA) expression, were enriched near the basal SG tip and had weak nuclear AR ([Figures 1](#fig1){ref-type="fig"}C and 1D). Nuclear AR is indicative of active AR signaling, and although the distribution of AR-positive cells in the SG was the same in the males and females, males tended to exhibit stronger nuclear staining than females ([Figure 1](#fig1){ref-type="fig"}B) ([@bib4]). Skin is also a local source of androgens ([@bib11], [@bib12]). Antibody specificity was confirmed by staining skin of *AR-TFM* mice, which lack functional ARs ([Figures S1](#figs1){ref-type="fig"}N, S1O, and S1P).

Differentiating sebocytes expressed lipogenic enzymes, such as fatty acid synthase (FASN) and peroxisome proliferator activated receptor γ (PPARγ) ([Figures 1](#fig1){ref-type="fig"}E and 1F). The largest sebocytes, located next to the SD, had low AR activity, expressed the *Myc* corepressor, B-lymphocyte induced maturation protein (BLIMP1) ([Figure 1](#fig1){ref-type="fig"}G), and were weakly positive for involucrin (IVL) ([@bib34]; [@bib64]) ([Figure 1](#fig1){ref-type="fig"}H). Although BLIMP1 is reported to be a sebocyte progenitor marker ([@bib24]), we only observed BLIMP1 expression in differentiating sebocytes ([@bib35]) and in keratinocytes of the SD, marked by IVL ([@bib31]) ([Figure 1](#fig1){ref-type="fig"}H, see arrows). This is consistent with previous reports that BLIMP1 is a marker of terminal differentiation in all epidermal lineages ([@bib10]; [@bib34]; [@bib35]; [@bib56]).

In wild-type mouse skin, MYC expression was higher in the interfollicular epidermis (IFE) and SG than HFs ([@bib47]), consistent with the finding that MYC activation favors differentiation along these lineages ([@bib3]; [@bib22]) ([Figure 1](#fig1){ref-type="fig"}J). MYC was expressed by differentiating, AR-positive sebocytes (detected with a 1:50 antibody dilution) ([Figure 1](#fig1){ref-type="fig"}K); however, the SG cells with highest levels of MYC (detected with a 1:200 antibody dilution) were basal, proliferating cells with low levels of AR ([Figures 1](#fig1){ref-type="fig"}L and 1M; [Figure S1](#figs1){ref-type="fig"}). Antibody specificity was confirmed on *K14MycER* and epidermal *Myc* knockout mice ([Figures S1](#figs1){ref-type="fig"}B--S1G, S1L, and S1M).

[Figure 1](#fig1){ref-type="fig"}N summarizes marker expression within the SG. Proliferative basal cells express the highest levels of MYC, whereas early differentiating sebocytes at the base of the SG have high levels of nuclear AR. Mid-differentiated cells exhibit high nuclear AR and express high levels of FASN and PPARγ. Late-stage differentiating sebocytes, in the upper part of the gland, exhibit low levels of AR activity, low expression of IVL, FASN, and PPARγ, and are BLIMP1+ve.

Effect of MYC on AR Activity {#sec2.2}
----------------------------

We next examined the effect of MYC activation on proliferation, differentiation, and AR activity in the epidermis. *K14MycER* mice were treated once with a low (0.1 mg) or high (1.5 mg) dose of 4OHT or vehicle (acetone) and examined for up to 8 days ([Figure S2](#figs2){ref-type="fig"}A). Control *K14MycER* mice treated with acetone and WT mice treated with 1.5 mg 4OHT were indistinguishable from untreated WT mice ([Figures 2](#fig2){ref-type="fig"}A--2G) ([@bib3]; [@bib7]). Although MYC activation is known to promote IFE thickening and to cause hair follicle abnormalities in *K14MycER* mice ([@bib3]), lineage tracing established that there was no relocation of cells from the IFE to the SG (data not shown).

Four days following low-dose 4OHT treatment, the SG of *K14MycER* mice was enlarged and the differentiation compartment expanded, as assessed by hematoxylin and eosin staining (H&E) staining ([Figure S2](#figs2){ref-type="fig"}B) and AR and FASN expression ([Figures 2](#fig2){ref-type="fig"}D--2I). On activation, the AR translocates to the nucleus, and this provides a readout of AR activity in vivo. A secondary readout is expression of FASN, which is an AR-responsive gene ([@bib53]). Differentiation was quantified ([Figure 2](#fig2){ref-type="fig"}C) by measuring the average cross-sectional area of the SG differentiation compartment ([Figure S2](#figs2){ref-type="fig"}B).

The SGs of *K14MycER* mice treated with 0.1 mg 4OHT enlarged by 4 days. This was not due to increased cell size ([Figure 2](#fig2){ref-type="fig"}J) but to an increased number of differentiating sebocytes ([Figure 2](#fig2){ref-type="fig"}K), including AR-positive cells (bracket, [Figure 2](#fig2){ref-type="fig"}I), which correlated with increased proliferation predominantly in basal layer cells, but also occasionally in differentiated cells. By 8 days, low-dose 4OHT-treated SGs were hyperplastic ([Figure 2](#fig2){ref-type="fig"}C; [Figures S4](#figs4){ref-type="fig"}A and S4C), exhibiting weakened expression of FASN ([Figures S4](#figs4){ref-type="fig"}B and S4D) and increased proliferation ([Figures S4](#figs4){ref-type="fig"}F and S4H).

In contrast to the effect of a low dose of 4OHT, by 4 days of high-dose 4OHT treatment, the SGs of *K14MycER* mice were filled with undifferentiated, immature sebocytes that frequently lacked nuclear AR and exhibited reduced FASN expression, indicating a collapse in AR signaling ([Figures 2](#fig2){ref-type="fig"}L and 2M). In some cases cytoplasmic AR was also reduced (see [Figure 6](#fig6){ref-type="fig"}C). This correlated with proliferative expansion of undifferentiated sebocytes at the base of the gland ([Figures 2](#fig2){ref-type="fig"}L and 2M). The reduction in the differentiation compartment ([Figure 2](#fig2){ref-type="fig"}C) was also observed 8 days after 4OHT treatment, the longest period for which mice could be monitored ([@bib7]). MYC activity remained elevated at 4 and 7--8 days after one dose of 4OHT, as assessed by qRT-PCR of *Nucleolin* ([Figure 2](#fig2){ref-type="fig"}P), an established MYC target gene ([@bib7]). In the IFE, formation of the cornified envelope persisted ([Figure 2](#fig2){ref-type="fig"}L), indicating the negative effects of high-dose MYC activation on differentiation were most pronounced in the SG lineage.

Although MYC stimulates AR activity and *AR* expression in prostate ([@bib40]), *Ar* mRNA levels in the skin of *K14MycER* mice were not affected by low or high doses of 4OHT ([Figures S2](#figs2){ref-type="fig"}D, S2E, S2F, and S2G). In AR-luciferase assays in immortalized human sebocytes, MYC repressed AR activity in the presence of testosterone but stimulated activity in cells treated with testosterone and the anti-androgen Casodex ([Figure S2](#figs2){ref-type="fig"}H), demonstrating MYC can regulate AR activity in a context-dependent manner.

These data suggest that in response to a low dose of 4OHT there is an accumulation of AR-positive differentiated sebocytes, whereas the impairment in sebaceous differentiation upon high-dose 4OHT treatment may reflect the inability of sebocytes to exit the proliferative basal cell compartment and acquire AR activity ([Figure 2](#fig2){ref-type="fig"}Q).

Effect of AR Activity on MYC-Induced SG Differentiation {#sec2.3}
-------------------------------------------------------

To test the role of the AR in MYC-induced sebocyte differentiation, *K14MycER* mice were crossed onto the *AR-Shah* x *AR-TFM* strain background. Mice inheriting the *AR-Shah* reporter allele have functional ARs ([@bib57]). Mice inheriting the *AR-TFM* mutation lack functional ARs ([@bib16]). Their SGs are morphologically normal ([Figure 3](#fig3){ref-type="fig"}A), although sebum production was not assessed ([@bib25]). *K14MycER AR-Shah* mice exhibited a similar response to low and high doses of 4OHT as the original *K14MycER* mice, although the SGs of control *K14MycER AR-Shah/AR-TFM* mice were slightly larger than original control *K14MycER* mice.

Compared to *K14MycER AR-Shah* mice, *K14MycER AR-TFM* mice showed a less pronounced induction of differentiation upon low-dose 4OHT treatment ([Figures 3](#fig3){ref-type="fig"}A--3C). FASN expression was reduced ([Figure 3](#fig3){ref-type="fig"}D), and there were increased numbers of Ki67+ve cells within the SG ([Figures 3](#fig3){ref-type="fig"}E and 3F). Similar results were observed when AR signaling in *K14MycER* mice was inhibited with high doses of Casodex ([Figures S3](#figs3){ref-type="fig"}I--S3K). As predicted from the block in differentiation, loss of AR did not affect the response to high-dose 4OHT ([Figures 3](#fig3){ref-type="fig"}A--3C). Although AR signaling is reported to regulate MYC protein stability ([@bib6]), we did not observe a significant change in *Nucleolin* mRNA expression ([Figure 3](#fig3){ref-type="fig"}G). We conclude that AR activity is required for efficient MYC-induced SG differentiation ([Figure 3](#fig3){ref-type="fig"}H). In contrast, genetic ablation of the *Ar* did not alter the IFE response to MYC or MYC-induced changes in telogen HFs ([@bib3]).

We next examined the effect of activating AR signaling with testosterone. Daily application of 2 mg testosterone had little effect on the number of differentiated sebocytes in WT 4OHT-treated and acetone-treated *K14MycER* mice of either gender, confirming that testosterone did not act directly on the MYCER fusion protein ([Figure 4](#fig4){ref-type="fig"}A). Testosterone did not enhance SG differentiation in *K14MycER* mice treated with a low dose of 4OHT for 4 days, suggesting that AR activity was already maximal in this condition ([Figures S4](#figs4){ref-type="fig"}G and S4H), although at 8 days SG hyperplasia was reduced ([Figures S4](#figs4){ref-type="fig"}E--S4H). In contrast, daily application of 2 mg testosterone to high-dose-treated *K14MycER* mice markedly stimulated differentiation and increased the SG differentiation compartment to the same extent as low-dose 4OHT ([Figures 4](#fig4){ref-type="fig"}A and 4D). Relocation of the AR to the nucleus and increased FASN expression confirmed testosterone restored AR activity ([Figure 4](#fig4){ref-type="fig"}B). Most sebocytes in skin treated with high-dose 4OHT and testosterone were AR and FASN+ve ([Figures 4](#fig4){ref-type="fig"}A and 4B), suggesting downregulation of AR activity might be required for later stages of maturation ([Figure 1](#fig1){ref-type="fig"}N). This was confirmed by examining the effect of Casodex on *K14MycER* mice treated with a low dose of 4OHT ([Figures S3](#figs3){ref-type="fig"}A--S3H).

The AR-dependent action of testosterone was confirmed by the competitive effect on SG differentiation of high doses of Casodex ([Figure 4](#fig4){ref-type="fig"}G) and by the inability of testosterone to rescue sebocyte differentiation in high-dose 4OHT *K14MycER AR-TFM* mice ([Figure 4](#fig4){ref-type="fig"}H). Testosterone increased levels of *Nucleolin* mRNA slightly, but the effect was not statistically significant ([Figure 4](#fig4){ref-type="fig"}F).

The differentiation promoting effects of testosterone in *K14MycER* mice treated with a high dose of 4OHT are summarized in [Figure 4](#fig4){ref-type="fig"}I.

Role of p53 in MYC-Induced Sebocyte Differentiation {#sec2.4}
---------------------------------------------------

Oncogenic levels of MYC can activate p53 via DNA damage ([@bib23]; [@bib39]; [@bib45]). p53 can inhibit *AR* gene expression ([@bib2]) and activity ([@bib59]) and block lipogenesis ([@bib18]). We therefore investigated whether p53 modulated the *K14MycER* sebaceous gland phenotype.

MYC activation induced DNA damage throughout the epidermis, as detected by γ-H2AX expression ([@bib45]) ([Figure 5](#fig5){ref-type="fig"}A). When MYC was activated with high-dose 4OHT, accumulation of active p53 was observed with an antibody to nuclear p53 ([Figures 5](#fig5){ref-type="fig"}B and 5G). Antibody specificity was confirmed on *p53null* mice ([Figure S5](#figs5){ref-type="fig"}A). However, the number of cells expressing the apoptotic marker cleaved caspase-3 was very low even when high levels of MYC were induced ([Figure 5](#fig5){ref-type="fig"}C). The induction of *p53* was confirmed by qRT-PCR ([Figure 5](#fig5){ref-type="fig"}D); in contrast, levels of total *p63* and *p73* were not significantly changed ([Figures 5](#fig5){ref-type="fig"}E and 5F). Given that *p53* was induced within 4 days of MYC activation, it is likely to be wild-type and not mutant.

When *K14MycER* mice were treated with 4OHT and testosterone, nuclear p53 protein (but not mRNA) levels were reduced throughout the epidermis ([Figures 5](#fig5){ref-type="fig"}H--5J). p53 activity was higher in *K14MycER AR-TFM* mice treated with a low dose of 4OHT than in *K14MycER AR-Shah* mice ([Figures 5](#fig5){ref-type="fig"}K and 5L), confirming that AR functions to repress p53 activity ([@bib41]).

To examine whether p53 activation in *K14MycER* mice treated with a high dose of 4OHT contributed to the inhibition of SG differentiation, mice were crossed onto a *p53null* background. In the SG, the effect was most profound and restored differentiation, with increased numbers of cells expressing nuclear AR and FASN, relative to mice that were heterozygous for *p53* ([Figures 6](#fig6){ref-type="fig"}A--6C). IVL showed some restoration in expression, but BLIMP1 expression was not restored ([Figure S5](#figs5){ref-type="fig"}B). Genetic ablation of *p53* partially reduced MYC-induced IFE hyperproliferative changes but did not alter MYC-induced changes in telogen HFs (data not shown).

*p53* deletion did not increase *Ar* ([Figure 6](#fig6){ref-type="fig"}D) or *Nucleolin* mRNA expression ([Figure 6](#fig6){ref-type="fig"}E) but increased MYC-dependent induction of *Fasn* and *Pparγ* ([Figures 6](#fig6){ref-type="fig"}F and 6G). Consistent with the stimulation of differentiation, there was reduced expression of *Ki67* ([Figure 6](#fig6){ref-type="fig"}H) and of *Keratin 7* (K7), a sebaceous lineage marker ([@bib65]) that is expressed in the SG basal layer ([@bib28]) ([Figure 6](#fig6){ref-type="fig"}I). Conversely, when p53 activation in 4OHT-treated *K14MycER* mice was enhanced by daily application of camptothecin (a topoisomerase inhibitor that causes DNA breaks and activates p53 \[[@bib52]\]) ([Figures S5](#figs5){ref-type="fig"}C--S5F), AR activity and proliferation in the SG lineage were reduced resulting in a reduction in gland size ([Figure S5](#figs5){ref-type="fig"}F). Testosterone coapplication partially antagonized the effects of camptothecin on the SG ([Figures S5](#figs5){ref-type="fig"}C--S5F).

We were able to generate a single *K14MycER p53null AR-TFM* mouse. This mouse exhibited reduced SG differentiation and enhanced proliferation compared to *K14MycER p53null* controls, with proliferation persisting in FASN+ve sebocytes. Sebocytes were also detected in the IFE ([Figure 6](#fig6){ref-type="fig"}J, see arrowhead).

Collectively, these experiments suggest that p53 activation resulting from DNA damage induced by high levels of MYC, contributes to the inhibition of SG differentiation and disruption of AR signaling ([Figure 6](#fig6){ref-type="fig"}K). Therefore, AR and p53 form an axis of mutual antagonism controlling the outcome of MYC activation in the SG. For further details of all prior results, please refer to the [Extended Results](#dtbox1){ref-type="boxed-text"}.

AR and p53 Expression in Human Sebaceous Tumors {#sec2.5}
-----------------------------------------------

To place our observations into the context of human patho-physiology, we examined expression of MYC, Ki67, AR, and p53 in human sebaceous tumors. Human SGs differ from mouse back skin SGs because they are larger and have a multilobed structure. In this regard the human SG resembles the murine preputial gland ([Figures 7](#fig7){ref-type="fig"}A and 7B). In both human scalp SGs and mouse preputial glands, we observed significant overlap in the expression of endogenous MYC and the AR, as well as MYC and the proliferative Ki67 basal compartment. We also observed active p53 in basal cells at low frequency ([Figures 7](#fig7){ref-type="fig"}A and 7B).

Differentiation status in tumors was assessed in H&E-stained sections and correlated inversely with the number of Ki67+ve cells, with one exception ([Figure 7](#fig7){ref-type="fig"}B). MYC was present in all tumors but often at very low levels, and the level of MYC expression exhibited no correlation with proliferation, differentiation status, or tumor type ([Figure 7](#fig7){ref-type="fig"}B).

Although p53 is often mutated in sebaceous carcinoma ([@bib29]), many of these transcriptionally inactive mutations can inhibit AR activity ([@bib43]). Tumors exhibiting reduced differentiation had a higher proportion of p53+ve sebocytes compared to AR+ve sebocytes, whereas those with increased differentiation had an equal or higher proportion of AR+ve sebocytes compared to p53+ve sebocytes. Three specimens exhibited multiple neoplasms within a single section, with distinct regions of adenoma (A) and carcinoma (C). These confirmed that the differences between high and low differentiation status tumors were not due to patient-specific effects ([Figures 7](#fig7){ref-type="fig"}B and 7C). Our results suggest that mutual antagonism of AR and p53 may contribute to progression of sebaceous carcinoma.

Extended ResultsMYC and AR Antibody Validation: [Figure S1](#figs1){ref-type="fig"}Endogenous c-MYC was expressed by differentiated and basal cells in the IFE and SG ([Figure S1](#figs1){ref-type="fig"}A). The highest expression was in IFE keratinocytes that were exiting the basal layer ([Figure S1](#figs1){ref-type="fig"}H), basal sebocytes ([Figure S1](#figs1){ref-type="fig"}I), and the bulb and matrix cells of anagen HFs ([Figures S1](#figs1){ref-type="fig"}J and S1K). *K14MycER* transgenic mice showed strong staining in the basal layer of the IFE, basal sebocytes and HF outer root sheath ([Figures S1](#figs1){ref-type="fig"}B--S1D), all regions of K14 expression. The same areas were positively labeled with an antibody to the ER domain of the MYCER fusion protein ([Figures S1](#figs1){ref-type="fig"}E--S1G). Staining for MYC or ER in *K14MycER* epidermis was similar in acetone and 4OHT treated skin, consistent with the fact that MYCER is expressed in the presence or absence of 4OHT ([@bib3]). The proportion of cells with nuclear MYC increased on addition of 4OHT (compare [Figures S1](#figs1){ref-type="fig"}C and S1D and [Figures S1](#figs1){ref-type="fig"}F and S1G), as previously shown in keratinocytes cultured from *K14MycER* mice ([@bib7]).c-MYC antibody specificity was confirmed by immunolabelling epidermis of WT and *K14MycER* mice and epidermis lacking c-MYC. *Myc null* epidermis was generated by topical application of 4OHT to *K14-CreER* x *Myc flox/flox* mice, kindly provided by Elisabete Nascimento and Michaela Frye ([@bib42]) ([Figures S1](#figs1){ref-type="fig"}L and S1M).*AR-TFM* mice lack functional AR expression, owing to a spontaneous single base pair change leading to a frame shift, premature stop codon and nonsense mediated RNA decay of *Ar* mRNA. A small N-terminal fragment of the AR may still be expressed in these mice at low levels but lacks nuclear function ([@bib16]). The AR antibody used in this study is raised to the N-terminus of the AR and detected nuclear AR in the lower sebaceous gland in mice with a functional *Ar* allele, such as the *AR-Shah* reporter mouse strain ([Figure S1](#figs1){ref-type="fig"}N), but not in *AR-TFM* mice ([Figure S1](#figs1){ref-type="fig"}O). At low frequency, the N-terminal AR fragment was occasionally detected as faint peri-nuclear speckling in sebocytes of in *AR-TFM* mice ([Figure S1](#figs1){ref-type="fig"}P).Further Characterization of K14MycER Mice: [Figures S2](#figs2){ref-type="fig"}A--S2GThe design of experiments involving topical application of chemical compounds is illustrated in [Figure S2](#figs2){ref-type="fig"}A. [Figure S2](#figs2){ref-type="fig"}B demonstrates how the size of the differentiated sebocyte compartment in each sebaceous gland was determined by measuring the cross-sectional area (marked by dashed yellow lines) occupied by pale pink sebocytes within each SG. [Figure S2](#figs2){ref-type="fig"}C demonstrates the effects on Ki67 labeling of treating *K14MycER* mice and WT mice with low or high dose 4OHT for 4 days and is quantified in [Figure 2](#fig2){ref-type="fig"}N.The *Ar* promoter is detected by ChIP of MYC in *K14MycER* epidermis ([@bib42]) and MYC can regulate *AR* expression and activity in the prostate ([@bib40]). As we observed an increase in the number of AR expressing sebocytes upon low dose MYC activation in K14MycER mice, we examined whether *Ar* mRNA expression in back skin was increased. There was no statistically significant change under the conditions tested ([Figure S2](#figs2){ref-type="fig"}D), in contrast to the increase in mRNA levels of the proliferation marker *Pcna* and the sebocyte lineage marker *Keratin 7* (*K7*) ([Figures S2](#figs2){ref-type="fig"}F and S2G). As 4OHT can inhibit Estrogen Receptor α, a positive regulator of the *AR* gene ([@bib66]), we tested if this was the case in skin. In WT mice we did see a small reduction in *Ar* expression but this was not statistically significant ([Figure S2](#figs2){ref-type="fig"}E).Effect of MYC on AR Activity: [Figure S2](#figs2){ref-type="fig"}HTo examine whether MYC activation modulated AR signaling, we performed AR-reporter luciferase assays in the human sebocyte line SebE6E7 that was immortalized by introduction of *HPV16 E6* and *E7* genes ([Figure S2](#figs2){ref-type="fig"}H) ([@bib34]). SebE6E7 cells exhibited low background AR reporter activity in the presence of DMSO, exogenous testosterone and the anti-androgen casodex, indicating that endogenous AR activity on androgen response elements was low ([Figure S2](#figs2){ref-type="fig"}H). However testosterone strongly increased AR activity in AR-transfected sebocytes and this increase was reduced by the addition of casodex ([Figure S2](#figs2){ref-type="fig"}H), confirming the pro and anti-androgen function of testosterone and Casodex, respectively.SebE6E7 cells transfected with *Myc* alone showed no changes in AR activity in the conditions tested. However when the *Ar* and *Myc* were co-transfected, MYC caused a reduction in AR activity in response to testosterone. This indicates that MYC can repress AR signaling in some contexts ([Figure S2](#figs2){ref-type="fig"}H). In contrast, in cells co-transfected with *Ar* and *Myc*, MYC promoted AR activity in the presence of Casodex and testosterone ([Figure S2](#figs2){ref-type="fig"}H). This may reflect context-dependent recruitment of transcriptional co-regulators to the AR by MYC.Effects of Casodex on K14MycER Mice: [Figure S3](#figs3){ref-type="fig"}Casodex is a clinically validated anti-androgen used to treat human prostate cancer. It acts in a variety of ways, such as forming inactive, DNA-bound AR transcriptional complexes, competing for AR binding with androgen and preventing heat-shock protein dissociation ([@bib72]). Since expression of the AR peaked at the onset of sebocytes differentiation but declined during later stages ([Figure 1](#fig1){ref-type="fig"}), we treated *K14MycER* mice for 4 days with a low dose of casodex to see how differentiation was affected.Daily low dose casodex treatment (4x2mg) in combination with a high dose 4OHT did not promote sebocyte differentiation in *K14MycER* mice, confirming that casodex had no agonist properties when combined with MYC activation in vivo ([Figures S3](#figs3){ref-type="fig"}A and S3C). However, when combined with a low dose of 4OHT, daily casodex treatment led to enlargement of the SG differentiation compartment ([Figures S3](#figs3){ref-type="fig"}B and S3C). This was not due to increased proliferation (data not shown) but rather to enlargement of individual sebocytes at the mid-phase of differentiation ([Figure S3](#figs3){ref-type="fig"}D, brackets), reflecting increased lipid accumulation. Late stage differentiation was unaffected ([Figure S3](#figs3){ref-type="fig"}E), as there was no increase in the number of mature sebocytes expressing IVL or BLIMP1.When 4x2mg casodex treatment was combined with 4x2mg testosterone and a high dose of 4OHT sebocytes differentiation was stimulated to a greater extent than with testosterone alone ([Figures S3](#figs3){ref-type="fig"}F and S3G). We interpret this result as testosterone stimulating the onset of differentiation by promoting AR-activity in early stages of maturation, while next casodex enhanced late stage differentiation by inhibiting the AR ([Figure S3](#figs3){ref-type="fig"}H).When low dose 4OHT *K14MycER* mice were treated with a higher dose of casodex (4x8mg) for 4 days, SG differentiation was impaired, mimicking the phenotype of *K14MycER AR-TFM* mice. The block in differentiation was overcome by addition of testosterone ([Figures S3](#figs3){ref-type="fig"}I and S3J). Application of 4x8mg casodex to WT mice or *K14MycER* mice in the absence of 4OHT did not affect skin histology, nor activate p53 signaling (data not shown).Our results indicate that in undifferentiated sebaceous gland cells, the AR functions as a differentiation enhancer by promoting cell cycle exit and triggering initial lipid accumulation. However, the AR inhibits the later stages of maturation. Our findings may explain some of the conflicting effects of androgens on sebocyte growth, proliferation and differentiation reported in vitro and in vivo ([@bib1]; [@bib63]).Sebaceous Gland Hyperplasia in K14MycER Mice: [Figure S4](#figs4){ref-type="fig"}Low dose treated *K14MycER* mice showed SG enlargement after 4 days, which progressed to SG hyperplasia by 8 days. While the overall differentiation compartment was expanded, this coincided with a partial reduction in AR activity, reduced FASN expression, and accumulation of sebocytes at the top of the gland, suggesting decreased turnover ([Figures S4](#figs4){ref-type="fig"}A--S4D). To test its functional significance, we treated mice with daily doses of 2mg testosterone. There was no effect for the first 4 days, which indicates that endogenous AR activity was maximal ([Figure S4](#figs4){ref-type="fig"}G). However at 8 days testosterone administration prevented the reduction in AR activity and significantly reduced SG hyperplasia ([Figures S4](#figs4){ref-type="fig"}E and S4G). Proliferation of SG progenitors and maturing sebocytes was reduced ([Figures S4](#figs4){ref-type="fig"}F and S4H). These data collectively suggest that AR has an anti-proliferative function. Whether human SG hyperplasia is also linked to androgens is debated ([@bib76]; [@bib77]; [@bib78]).Effects of Inducing p53: [Figure S5](#figs5){ref-type="fig"}To test if p53 activation disrupted SG homeostasis, male *K14MycER* mice where given a low dose of 4OHT and challenged with daily administration of the pro-apoptotic drug camptothecin for 4 days. Some mice also received daily testosterone doses. Camptothecin affected the whole epidermis, but in particular impacted the SG lineage and reduced the SG differentiation compartment ([Figure S5](#figs5){ref-type="fig"}C). Camptothecin accelerated clearance of DNA damaged cells marked by γ-H2AX ([Figure S5](#figs5){ref-type="fig"}D), increased p53 activity ([Figure S5](#figs5){ref-type="fig"}E) and promoted caspase-3 cleavage ([Figure S5](#figs5){ref-type="fig"}G). Topical application of camptothecin also triggered reduction of nuclear AR-positive and FASN-positive sebocytes ([Figure S5](#figs5){ref-type="fig"}F). Testosterone administration had a modest protective effect by offsetting SG shrinkage, reducing cleaved capase-3 induction, promoting SG AR activity and increasing FASN expression. Testosterone also appeared to decrease induction of p53 throughout the epidermis. These data confirm that an apoptotic level of p53 activation impairs maintenance of the SG lineage by impacting both proliferation and differentiation, and that the AR has a significant role in antagonising the effect of p53 activation.

Discussion {#sec3}
==========

Our findings support a model whereby when MYC is overactivated with a low dose of 4OHT, the AR inhibits proliferation and stimulates the onset of differentiation. However, greater MYC activity induces a p53 response as a result of DNA-damage, consistent with previous observations ([@bib45]). The p53 response (increased nuclear p53 protein and its downstream consequences) inhibits AR activity and without the AR to trigger the onset of differentiation, cells continue proliferating in response to MYC and accumulate as undifferentiated sebocytes. The nonapoptotic p53 response could reflect the reported ability of MYC to inhibit p53-mediated apoptosis ([@bib9]).

The AR can promote or retard sebocyte proliferation, depending on androgen type and the body site from which sebocytes are derived ([@bib1]). The phenotype of *AR-TFM* mice highlights the antiproliferative role of the AR in murine back skin following MYC activation but shows that the AR is not required for SG differentiation during normal skin homeostasis ([@bib5]; [@bib50]). In rodent meibomian sebocytes, the AR functions early in differentiation to initiate lipogenesis and lipid metabolism via transcriptional regulation of genes, such as *Fasn* and *Pparδ* ([@bib53], [@bib54]). Placing the AR upstream of the lipogenic program is consistent with our observations because peak AR expression was observed just before the onset of differentiation and then persisted during the first accumulation of lipids, marked by FASN and PPARγ. Downregulation of AR activity late in sebocyte differentiation may play a role in the final stages of sebocyte maturation because low doses of the anti-androgen Casodex facilitated lipid accumulation ([Figure S3](#figs3){ref-type="fig"}D). The AR also appears to have a role in repressing p53 activation ([Figures 5](#fig5){ref-type="fig"}H, 5I, 5K, and 5L; [Figures S4](#figs4){ref-type="fig"}I and S4J and [S5](#figs5){ref-type="fig"}C--S5G), as previously reported in prostate ([@bib41]).

Loss of p53, like loss of AR, did not affect SG homeostasis, that is, the normal balance between proliferation and differentiation, although p53 is expressed in undifferentiated human and mouse sebocytes ([Figures 7](#fig7){ref-type="fig"}A and 7B). p53 deletion restored SG differentiation in high-dose 4OHT-treated *K14MycER* mice, and this rescue was diminished in the absence of AR signaling, highlighting the antagonistic effects of AR and p53. Additional MYC-induced differentiation factors may be inhibited by p53, such as PPARγ ([Figure 6](#fig6){ref-type="fig"}G), which can bypass the requirement for androgens in normal SG differentiation ([@bib51]). Although p53 activation in *K14MycER* mice did not induce apoptosis, epidermal *Setd8* deletion triggers apoptotic p53 activation, resulting in loss of the IFE and SGs ([@bib15]). Increasing p53 activity with camptothecin ([Figures S5](#figs5){ref-type="fig"}E and S5G) resulted in an apoptotic phenotype that was similar to the early stages of epidermal *Setd8* deletion ([@bib15]), demonstrating that different thresholds of p53 activation can have distinct outcomes.

Our observation that AR and p53 are mutually antagonistic in regulating MYC-induced sebocyte differentiation is relevant to human sebaceous carcinoma. As in the mouse model, increased numbers of p53-positive sebocytes correlated fewer AR-positive sebocytes, reduced differentiation, and poor prognosis in the tumors ([Figure 7](#fig7){ref-type="fig"}) ([@bib5]; [@bib19]; [@bib20]; [@bib26]). MYC was detected in all the tumors we examined and did not correlate with Ki67 expression, consistent with a role of MYC in regulating both proliferation and differentiation. Although in contrast to *K14MycER* mice, p53 is often mutated in sebaceous carcinoma ([@bib29]) as a result of DNA damage, and these mutations are still capable of inhibiting AR activity when tested in prostate cells ([@bib43]). It is possible therefore that within p53-positive sebaceous carcinomas, p53 accumulation impairs AR signaling without inhibiting proliferation ([Figures 5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"}, and [7](#fig7){ref-type="fig"}). p53 could interfere posttranslationally with AR activity by disrupting AR homodimerization and DNA binding ([@bib59]). Alternatively, because AR and p53 protein stability are both regulated by murine double minute 2 (MDM2), AR downregulation in tumors could be due to activation of MDM2 in response to increased p53 ([@bib30]; [@bib33]). Finally, p53 could indirectly affect AR signaling by reducing local androgen synthesis in the skin ([@bib11], [@bib12]; [@bib18]). The observation that p53 deletion confers resistance to spontaneous and chemically induced epidermal papillomas and squamous cell carcinomas ([@bib17]) suggests that p53 activation also influences differentiation in the interfollicular epidermis.

In conclusion, our study identifies an AR/p53 axis that determines the outcome of MYC overactivation in the SG. When MYC activity is moderately elevated, the AR functions to prevent p53 activation, terminate proliferation, and promote the onset of differentiation. However, in response to high MYC activity, p53 can block AR signaling and thereby inhibit differentiation, leading to expansion of undifferentiated sebocytes. Our observations help to explain how MYC, an oncogene, can trigger SG differentiation and how activation of p53 can facilitate proliferation of undifferentiated cells in human sebaceous carcinomas via downregulation of the AR.

Experimental Procedures {#sec4}
=======================

Transgenic Mice {#sec4.1}
---------------

*K14MycER* transgenic mouse founder line 2184C.1 ([@bib3]) was used for this study and maintained on a C57/Bl6 x CBA F1 background. The other strains of mice used in crosses are described in the [Extended Experimental Procedures](#dtbox2){ref-type="boxed-text"}. Mice were treated once with 100 μl acetone or 0.1 or 1.5 mg 4OHT (Sigma-Aldrich H6278; Sigma-Aldrich, St. Louis, MO, USA) dissolved in 100 μl acetone. 4OHT was applied to clipped lower back skin, and mice were analyzed 1--8 days later. In some experiments, mice additionally received daily doses of 100 μl of acetone and/or 2 mg testosterone (Testos; Sigma-Aldrich T1500) and/or 2, 4, or 8 mg Casodex (bicalutamide anti-androgen; Sigma-Aldrich B9061) in 100 μl acetone. See [Figure S2](#figs2){ref-type="fig"}A for treatment illustration and the [Extended Experimental Procedures](#dtbox2){ref-type="boxed-text"}.

All experiments were performed on a minimum of three mice per condition, with the exception of *K14MycER p53null AR-TFM* mice. Experiments were subject to Cancer Research UK ethical review and performed under the terms of a UK Government Home Office license.

Immunofluorescence, Immunohistochemistry, and Microscopy {#sec4.2}
--------------------------------------------------------

Primary and secondary antibodies and labeling procedures are described in the [Extended Experimental Procedures](#dtbox2){ref-type="boxed-text"} and [Table S1](#mmc1){ref-type="supplementary-material"}. Immunofluorescence (IF) slides were counterstained with the nuclear dye DAPI. Immunohistochemistry slides were counterstained with hematoxylin.

qRT-PCR {#sec4.3}
-------

RNA isolation, cDNA preparation, and qRT-PCR were performed using the Trizol method as described previously ([@bib15]) and described in detail in the [Extended Experimental Procedures](#dtbox2){ref-type="boxed-text"}.

Human Tissue {#sec4.4}
------------

Samples were collected, diagnosed, and provided by H.G. and S.R.Q. or S.A. and K.N. All samples were obtained with informed consent and processed for research in accordance with the recommendations of the relevant local ethics committees: CRUK Cambridge Research Institute (number 08/H0306/30), German Medical Council, and/or the Japanese Ministry of Health, Labor, and Welfare.

Quantitation and Statistics {#sec4.5}
---------------------------

Quantitation of Ki67, p53+ve cells, and the average cross-sectional area of the SG differentiation compartment were determined from at least ten 10x images of H&E-stained tissue sections per mouse. Only vertical sections of back skin were quantitated. The SG differentiation compartment was identified in H&E sections on the basis of differentiating sebocytes exhibiting pale and enlarged cytoplasm from lipid accumulation. Examples of how measurements were made are shown in [Figure S2](#figs2){ref-type="fig"}B. Statistical analysis was performed using the unpaired Student's t test.

Extended Experimental ProceduresTransgenic MiceThe following additional strains were used in this analysis: *p53null* mice (B6.129S2-Trp53 tm1Tyj/J; Jackson Laboratory 002101), *AR-Shah* mice (B6.129S-Artm1Rax/ShahJ; Jackson Laboratory 012374) and *Eda (Ta-6J)* x *AR-TFM* mice (B6.Cg-Aw-J EdaTa-6J +/+ ArTfm/J; Jackson Laboratory 001809). *p53null* and *AR-Shah* strains were first crossed onto a C57/Bl6 x CBA F1 background to match our *K14MycER* mice prior to further breeding. *AR-Shah* and *Eda (Ta-6J)* x *AR-TFM* mice were first crossed to create a compound strain of AR-Shah and AR-TFM and bred onto a near C57/Bl6 x CBA F1 background, before further crossing with *K14MycER* mice.The *AR-Shah* allele contains an *IRES* Alkaline phosphatase *IRES* LacZ reporter cassette knocked into the *Ar* locus following the stop codon ([@bib57]) and was used to track the *AR-TFM* allele by exclusion. Under our breeding strategy, male mice were born with either the AR-competent *AR-Shah* gene or AR-functionless *AR-TFM* gene. The *AR-Shah AR-TFM* strain was further crossed with *K14MycER* and *K14MycER p53null* mice. These mice were 53.125% C57/Bl6 46.875% CBA and 51.56% C57/Bl6 48.44% CBA respectively.Experiments were performed on male and female mice that were typically aged 7-9 weeks corresponding to the telogen phase of the hair growth cycle ([@bib74]). However, *K14MycER AR-TFM* and *K14MycER p53null AR-TFM* mice were treated at 6-6.5weeks, as they enter telogen prematurely ([@bib75]). Any mice that strongly re-entered anagen during the course of an experiment were excluded from analysis.As reported previously, no significant effects of gender on the phenotype of 4OHT treated *K14MycER* mice were observed ([@bib3]; [@bib7]). This is consistent with observations that the skin is a site of androgen synthesis regardless of gender ([@bib11], [@bib12]). For *AR-Shah AR-TFM* strains, *AR-Shah/Y* true males, homozygous *AR-Shah* females and *AR-TFM/Y* feminised males were used for analysis.The biological activity of topical applications of 4OHT, testosterone and camptothecin to skin has been reported previously ([@bib7]; [@bib68], [@bib69]; [@bib70]). Topical application of anti-androgens is also a well-established procedure ([@bib73]). In addition to 4OHT, some mice received daily topical doses of 100 μl 10% DMSO or 0.5 or 1mg camptothecin (Campto, Sigma-Aldrich C9911) in 100 μl 10% DMSO. Camptothecin was insoluble and applied as an emulsion.Immunofluorescence and Immunohistochemical LabelingPrimary antibodies are listed in [Table S1](#mmc1){ref-type="supplementary-material"}. Secondary antibodies used at 1:600 dilution were Alexa-Fluor 488, 555, 594, or 647-conjugated goat anti-rabbit, anti-mouse or anti-rat IgG or donkey anti-rabbit, anti-mouse, anti-goat or anti-rat IgG (Invitrogen Molecular Probes). Secondary antibodies used at 1:200 dilution were donkey polyclonal anti-Rat IgG-H&L pre-absorbed-Dylight 488 (Abcam ab102260), donkey polyclonal anti-mouse IgG-H&L pre-absorbed-Dylight 649 (Abcam ab98797) and donkey polyclonal anti-goat IgG-H&L pre-absorbed-Dylight 549 (Abcam ab96936). Other secondaries were Streptavidin-Alexa-Fluor 488 (Invitrogen Molecular Probes S11223), diluted 1:250, and rabbit polyclonal anti-mouse-Biotin (Abcam ab97044), Biotin-SP-AffiniPure Donkey Anti- Rabbit IgG (H^+^L) (Jackson ImmunoResearch laboratories Inc 711-065-152) used at 1:300 dilution from a 0.65mg/ml stock solution.Samples of mouse back skin were fixed overnight in 4% paraformaldehyde or 10% neutral buffered formalin and stored in 70% ethanol prior to embedding in paraffin or else frozen in OCT compound (Miles) for horizontal whole mounts ([@bib67]). Paraffin sections were dewaxed in xylene 2x for 5mins and sequentially washed with 100% Ethanol 2x 3mins, 96% Ethanol 1x1min, 80% Ethanol 1x1min, distilled water 2x1min, then placed in PBS. Dewaxed sections were transferred to a rice cooker and boiled for 20 min in standard Sodium Citrate Tribasic pH6 buffer. Sections were then cooled for 20mins in PBS, and blocked/permeabilized in 10% Bovine or Goat Serum, 1% BSA, 0.1% Triton X-100, with 1 drop of Fish Scale gelatin (per 20ml) in PBS for 10-20 min. Primary antibodies were applied in 10% Bovine or Goat Serum, 1% BSA+ drop of Fish Scale gelatin in PBS without Triton X-100, for 2 hr at room temperature. Following 3 washes in PBS, secondary antibodies and 40-6-diamidino-2-phenylindole (DAPI), (in same buffer as primary) were incubated with sections for 1.5-2 hr at room temperature. After 3 washes in PBS and 1 wash in distilled water sections were mounted in Slow Fade Gold reagent (Invitrogen).The procedure for automated immunohistochemistry was to dewax and rehydrate sections on a Leica ST 5020 and then stain sections on a Leica Bond Max or Ventana Discovery. On the Leica Bond Max p53 was labeled with anti-p53 (DO-7) followed a 30' citrate treatment, and AR was labeled with anti-AR (AR27) followed by a 20' EDTA treatment using the Leica Bond Polymer system (DS9800). AR was detected with anti-AR (N-20) followed by a 20' EDTA treatment, and Ki67 with anti-Ki67 (Tec-3) followed by a 20' citrate pre-treatment, performed using Vision Biosystems Bond Intense R biotin/streptavidin Detection system (DS9263). Signals were enhanced by 10' incubation with Bond DAB Enhancer (AR9432-Lecia). All antigen retrieval was performed at 100°C.The Ventana Discovery system was used for labeling sections with anti-c-MYC, anti-p53 (CM5) and anti-Ki67 (SP6) as described previously ([@bib15]; [@bib42]). Mouse on mouse FASN staining was performed with a modified protocol whereby a mixture of non-immune mouse IgG1 (Abcam ab81032, 1:100) and non-immune rabbit IgG (SCBT sc-2027, 1:50) was applied during the first antibody incubation. Mouse anti-FASN antibody (1:50) was pre-complexed with rabbit anti-mouse-Biotin (1:250) for a minimum of 15minutes in 1xPBS at room temperature, and any remaining unbound secondary antibody was sequestered by addition of an excess of non-immune mouse IgG (1:100).Microscopy was performed with a Leica SP5 confocal, Zeiss Axiophot or Zeiss AxioImager M2 fluorescent microscope, using 10x and 20x objectives.qRT-PCR0.25-0.5cm^2^ pieces of back skin were collected, snap frozen and stored in liquid nitrogen until use. All surfaces and equipment were cleaned with RNase Zap. Samples were placed into round-bottom tubes containing 1.5ml Trizol and homogenized using a polytron (setting 11-15), then transferred into 2ml RNase-free tubes and placed on ice until all samples had been processed. Between samples, the polytron was washed sequentially with 1x9ml DEPC water, 1x9ml 70% Ethanol in DEPC water, 1x9ml 1M NaOH in DEPC water and 3x9ml DEPC water, on setting 15. Samples were incubated at RT for 5′ and then 300ul of BCP reagent was added. Samples were capped and shaken vigorously for 15 s until mixed, and left to separate for an additional 3′ at RT. Samples were next centrifuged for 15' at 12,000 g at 4°C and the aqueous layer transferred to fresh RNase-free tubes. 750ul Isopropanol was added and mixed by inversion then incubated for 10' at RT before being centrifuged for 10' at 12,000 g at 4°C. The supernatant was discarded and the pellet washed in 1ml 70% Ethanol in DEPC, then centrifuged for 1' at 12,000 g at 4°C. The supernatant was again discarded, samples were again centrifuged for 1' at 12,000 g at 4°C and the last traces of ethanol were removed. Samples were left to dry for 10' in a fume hood before addition of 50ul nuclease-free water. Samples were incubated for 10' at 55°C to resuspend RNA. RNA concentration was determined using a nanodrop and preparations stored at −80°C until use. RNAase-free plugged tips were used throughout.2 μg of RNA was collected and treated with RQ1 DNase (Promega M610A) according to the manufacturer's protocol. cDNA was prepared using Superscript III First-Strand Synthesis SuperMix for qRT-PCR Kit (Invitrogen 11752-250). For qRT-PCR 20 μl reactions were established in 96well plate format, each containing 1 μl of probe, 1 μl cDNA, 8 μl nuclease-free water and 10 μl of 2x Taqman Fast universal reaction master mix (Applied Biosystems). Reactions were performed on a StepOne Real-time PCR machine (Applied Biosystems) using a quick-start protocol. Quantitation was performed using the ΔCT method and normalized relative to GAPDH. Taqman probes (Applied Biosystems) were as follows: *Gapdh* 4352932-1005035, *Ar* Mm00442688_m1, *Keratin 7* Mm00466677_m1, *Fasn* Mm00662319_m1, *Ki67* Mm01278617_m1, *Pcna* Mm00448100_g1, *Pparγ* Mm011843222_m1, *Nucleolin* Mm01290591_m1, *p53* Mm01337166_mH, *pan p63* Mm00495788_m1, and *pan p73* Mm00660220_m1.Generation of PlasmidspRetroQ-mCherry, a mammalian mCherry expression construct, was cloned by excision of mCherry from pmCherry-N1 (Clontech) and exchange with AcGFP in pRetroQ-AcGFP-N1 (Clontech). pRetroQ-Flag-AR-T2A-mCherry, a mammalian dual non-covalently-linked AR and mCherry expression construct, was cloned by PCR addition of an N-terminal Flag-tag and C-terminal T2A linkage sequence to mouse AR cDNA using template pENTR233.1-AR (Clone ID 100016477, Source Bioscience) with product subcloned into pRetroQ-mCherry. pCDNA4-Myc, a kind gift from Dr. Alastair Lamb (Neal laboratory, Cambridge Research Institute, Cancer Research UK), was generated by excision of Myc from pBABEpuro c-mycER ([@bib71]) and ligation into pCDNA4 (Invitrogen). Plasmid DNA was prepared using QIAGEN products.AR Reporter Luciferase AssaysSebE6E7 immortalized human sebocytes were cultured in serum and growth factor supplemented Sebomed medium (Biochrom) as previously described ([@bib34]). SebE6E7 sebocytes were seeded in 48-well plates at a density of 4-5x10^4^ cells per well and allowed to adhere overnight. Adherent sebocytes were transfected with 0.2 μl Xfect (Clontech), mixed with 0.24 μg pRetroQ-mCherry (parent-vector) or pRetroQ-Flag-AR-T2A-mCherry (AR) and 0.24 μg pCDNA4 (parent-vector) or pCDNA4-Myc (Myc), with 0.2 μg pTA-Luc (background control, LR0000, Panomics) or pAR-Luc (AR-reporter, LR0007, Panomics) firefly luciferase plasmids and 0.02 μg pCMV-RL Renilla luciferase reporter (Promega) for 4 hr according to the manufacturer's protocol. Total DNA was maintained at 0.7 μg per well by inclusion of parent-vectors as needed.Sebocytes were incubated in supplemented Sebomed medium overnight, then transferred to medium containing 20 μM testosterone (T1500, Sigma-Aldrich) and/or 10 μM casodex (Bicalutamide, B9061, Sigma-Aldrich) or DMSO-vehicle for 24 hr. Testosterone and casodex stocks in DMSO were prepared at 1000x. Cells were lysed and assayed using the Promega dual luciferase reporter kit according to the manufacturer's instructions. Data were collected on a Glomax luminometer (Promega). Luciferase values were normalized by dividing with Renilla luciferase activity values to adjust for transfection efficiency. Each experiment was performed in triplicate and values averaged for each condition. pAR-Luc data are expressed as fold change over values obtained from equivalent conditions with pTA-Luc to adjust for global transcriptional changes and highlight Androgen Response Element-dependent changes. Changes are expressed relative to vehicle (defined as 1) for each transfection combination. This experiment was performed 5 times with independent cell populations.
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![Expression of the AR and Other Markers in the SG\
(A--M) Adult WT mouse telogen back skin labeled with antibodies to the markers indicated. (H) Arrows indicate a cell of either sebaceous duct (SD) or sebaceous gland lineage (SG). (J--M) c-MYC antibody dilution is indicated. SG is outlined by dashed line in (F). Arrowheads indicate basal c-MYC +ve sebocytes. (I) Asterisks indicate autofluorescent hair shaft.\
(N) Schematic of SG showing undifferentiated sebocytes and early, mid, and late stages of terminal differentiation. Circular arrow indicates proliferating cells. HF, hair follicle; SD, sebaceous duct; PC, progenitor cell.\
Scale bars, 40 μm. See also [Figure S1](#figs1){ref-type="fig"}.](gr1){#fig1}

![Effects of MYC Activation on SG Proliferation and Differentiation\
(A--Q) WT and *K14MycER (Myc:)* mouse telogen back skin was untreated, acetone-treated (vehicle), or 4OHT-treated, as indicated. (A, D, F, H, and L) Skin sections were stained with H&E. (B, E, G, I, and M) Skin sections were stained with the antibodies shown. White bracket indicates expansion of AR-expressing sebocytes in (I). (C) Quantitation of SG differentiation compartment (average cross-sectional area occupied by differentiated sebocytes per SG) for the experiment described above. Red line represents average untreated WT measurement, and dashed red lines represent SEM. (J) Quantification of average size of individual differentiated sebocytes (cross-sectional area). (K) Average number of differentiated sebocytes per SG cross-section. (N) Quantitation of Ki67+ve sebocytes per SG. Red line represents untreated WT measurement. (O and P) qRT-PCR of *Ki67* and *Nucleolin* mRNA levels relative to *Gapdh*. (Q) Schematic summary of changes relative to WT SG of treating *K14MycER* mice with low or high dose 4OHT. See [Figure 1](#fig1){ref-type="fig"}N for stages in sebocytes differentiation. Increases in cell number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by −.\
Three to nine mice were examined per condition. Error bars represent SEM \#p \< 0.06, ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.005. Scale bars 40 μm. See also [Figure S2](#figs2){ref-type="fig"}.](gr2){#fig2}

![Effect of Loss of AR Function during MYC Activation\
(A--H) WT and *K14MycER* mice *(Myc:)* were crossed with *AR-Shah* or *AR-TFM* mice and treated as indicated. (A and B) Skin sections were stained with H&E. (C) Quantitation of size of SG differentiation compartment. (D and E) Immunostaining (brown) for antibodies indicated. (F) Quantitation of Ki67+ve sebocytes. (G) qRT-PCR of *Nucleolin* mRNA levels relative to *Gapdh*. (H) Schematic summary of the effects of AR loss of function. See [Figure 1](#fig1){ref-type="fig"}N for stages in sebocyte differentiation. Increases in cell number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by −.\
Three to seven mice were examined per condition. Error bars represent SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.005. Scale bars, 40 μm. See also [Figure S3](#figs3){ref-type="fig"}.](gr3){#fig3}

![Testosterone Modulation of AR Activity during MYC Activation\
(A--I) WT, *K14MycER* (Myc:), *K14MycER AR-Shah*, and *K14MycER AR-TFM* mice were treated as indicated. (A) Skin sections were stained with H&E. (B and C) Skin sections were stained with the antibodies shown. (D) Quantitation of the SG differentiation compartment. (E) Quantitation of Ki67+ve sebocytes per SG. (F) qRT-PCR of *Nucleolin* (Nuc) mRNA levels relative to *Gapdh*. (G and H) Skin sections were stained with H&E. Quantitation of SG differentiation compartment size is shown. (I) Schematic summary of the effect of testosterone on *K14MycER* mice treated with high-dose 4OHT. See [Figure 1](#fig1){ref-type="fig"}N for stages in sebocytes differentiation. Increases in cell number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by −.\
Three to six mice were examined per condition. Error bars represent SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.005. Scale bars, 40 μm. See also [Figures S3](#figs3){ref-type="fig"} and [S4](#figs4){ref-type="fig"}.](gr4){#fig4}

![Effect of MYC and AR Activation on p53 Expression, DNA Double Strand Breaks, and Apoptosis\
(A--L) WT and *K14MycER* (Myc:) mice were treated as indicated. (A) Skin sections were labeled with antibodies to γ-H2AX with DAPI nuclear counterstain. (B, H, and K) Skin sections were labeled with antibodies to p53 (arrowheads indicate positive nuclei). (C) Skin sections were labeled with antibodies to cleaved caspase 3. (D--F) qRT-PCR of mRNA levels relative to *Gapdh*. (G, I, and L) Quantitation of p53+ve nuclei per unit area of skin (HF, SG, and overlying IFE). (J) qRT-PCR of *p53* mRNA levels relative to *Gapdh*.\
Three to nine mice were examined per condition. Error bars represent SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01. Scale bars, 40 μm.](gr5){#fig5}

![Loss of p53 Function during MYC Activation\
(A--K) Mice were treated as indicated. (A and J) Skin sections were stained with H&E. (B) Quantitation of SG differentiation compartment. (C and J) Skin sections were stained with the antibodies shown. Arrowhead in (J) indicates sebocyte differentiation within the IFE. (D--I) qRT-PCR of mRNA levels relative to *Gapdh*. (K) Schematic summary of effects of loss of p53 and combined loss of p53 and the AR. See [Figure 1](#fig1){ref-type="fig"}N for stages in sebocytes differentiation. Increases in cell number are represented by +, ++, or +++, according to the strength of the effect. Reduction in cell number is represented by −.\
Scale bars, 40 μm. Error bars represent SEM. Three to five mice were examined per condition, except n = 1 for triple cross. NS, not significant. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005. See also [Figure S5](#figs5){ref-type="fig"}.](gr6){#fig6}

![p53 and AR Expression in Human Sebaceous Tumors\
(A) Mouse preputial gland sections were stained with H&E or the antibodies shown. Diagram on H&E indicates differentiation within each sebaceous lobe. Arrowheads indicate p53+ve cells.\
(B) Representative tumor sections are stained with H&E or the antibodies shown. Scale bars 40 μm.\
(C) Summary of immunostaining and differentiation status of individual tumors. Staining was scored as follows. − negative, −/+ almost entirely negative, + to ++++ increasing proportion of positive cells, with ++++ indicating almost every cell positive.](gr7){#fig7}

![MYC and AR Antibody Validation on Sections of Mouse Back Skin, Related to [Figure 1](#fig1){ref-type="fig"}\
(A--D and H--M) Labeling with anti-cMYC antibody at the dilutions shown. WT: wild-type; Myc: MycER; c-Myc KO: deletion of *Myc* via *K14CreER*. Homozygous *c-Myc floxed* x *K14CreER* transgenics were treated with 1.5mg 4OHT every second day for a minimum of 21 days.\
(E--G) Labeling with ERα antibody to detect MYCER fusion protein.\
(N, O, and P) AR antibody labeling on *AR-Shah* and *AR-TFM* mice.\
Scale bars 40 μm.](figs1){#figs1}

![Further Characterization of *K14MycER* Mice and Effects of MYC activation on AR Signaling, Related to [Figure 2](#fig2){ref-type="fig"}\
(A) Scheme of experimental treatments.\
(B) Examples of differentiated SG compartment, (cross-sectional area occupied by differentiated sebocytes within yellow-dashed regions).\
(C) Ki67 labeling of *K14MycER* and WT control mice 4 days following treatment, quantified in [Figure 2](#fig2){ref-type="fig"}N.\
(D--G) qRT-PCR of mRNA levels of *Ar* (D, E), *Pcna* (F), and *K7* (G) relative to *Gapdh*. Error bars represent SEM.\
(H) AR-reporter luciferase assays in SebE6E7 human immortalized sebocytes. Data are means of 5 independent experiments ± SEM. NS = not significant, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005.\
Scale bars 40 μm.](figs2){#figs2}

![Casodex Treatment of *K14MycER* Mice, Related to [Figure 4](#fig4){ref-type="fig"}\
(A--K) Back skin of *K14MycER* mice (Myc:) was stained with H&E (A, B, and F) or labeled with the antibodies shown (D, E, I, and J). Skin in (I) was from a cross with *AR-TFM*. White brackets in (D) indicate differences in size of individual sebocytes. (C, G, and K) Quantitation of SG differentiation compartment. (H) Schematic summary of changes relative to WT SG of treating *K14MycER* mice with high dose 4OHT in the presence or absence of casodex. See [Figure 1](#fig1){ref-type="fig"}N for stages in sebocytes differentiation. Increases in cell number are represented by +, ++ or +++, according to the strength of the effect. Reduction in cell number is represented by -.\
3-5 mice were examined per condition. Error bars represent SEM. NS = not significant, ^∗^p \< 0.05. Scale bars 40 μm.](figs3){#figs3}

![*K14MycER* Sebaceous Gland Hyperplasia, Related to [Figure 4](#fig4){ref-type="fig"}\
(A, C, and E) H&E, (B and D) AR and FASN, (F) Ki67 and (I) p53 staining of wild-type (WT) and *K14MycER* (Myc:) mice.\
(G) Quantitation of size of SG differentiation compartment. H) Quantitation of Ki67 positive cells per sebaceous gland.\
(J) Quantitation of number of p53 positive sebocytes per unit area of skin.\
3 mice were examined per condition, Error bars represent SEM, \#p \< 0.06, ^∗^p \< 0.05, ^∗∗∗^p \< 0.005. Scale bars 40 μm.](figs4){#figs4}

![Effect on *K14MycER* Mice of Activating p53 with Camptothecin, Related to [Figure 6](#fig6){ref-type="fig"}\
(A) Validation of p53 antibody staining.\
(B) Immunostaining of BLIMP1 and Involucrin (IVL).\
(C) H&E staining. Graph demonstrates quantitation of SG differentiation compartment.\
(D) γ-H2AX, (E) p53, (F) PCNA, AR and FASN, (G) Cleaved caspase-3 labeling. White arrowheads indicate AR-positive sebocytes.\
3-5 mice were examined per condition. Error bars represent SEM, \#p \< 0.06, ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.005. Scale bars 40 μm.](figs5){#figs5}
